|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Study of Anti-CD19 Chimeric Antigen Receptor T Cells(PZ01) for Relapsed/ Refractory B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma
The major aim of this research is to assess the feasibility, safety and effectiveness of CD19 CAR-T Cell Therapy for Relapsed/ Refractory Acute Lymphoblastic Leukemia/ B cell Lymphoma patients who have applied it.
100 Clinical Results associated with Pinze Lifetechnology Co. Ltd.
0 Patents (Medical) associated with Pinze Lifetechnology Co. Ltd.
100 Deals associated with Pinze Lifetechnology Co. Ltd.
100 Translational Medicine associated with Pinze Lifetechnology Co. Ltd.